What is the mechanism of action of nintedanib/Vigat and how it affects the efficacy

Nintedanib (Nintedanib) is an oral multi-target tyrosine kinase inhibitor, mainly used to treat idiopathic pulmonary fibrosis (IPF) and other types of fibrosis-related diseases. Its mechanism of action enables it to intervene in the pathological process of the disease through multiple pathways, thereby effectively slowing down the progression of the disease.

1. Multi-target inhibitory effect:

1) Type B vascular endothelial growth factor receptor (VEGFR): Nintedanib can inhibit the VEGFR signaling pathway, thereby reducing angiogenesis and preventing the formation of abnormal blood vessels, which is crucial for controlling pulmonary fibrosis.

2) Fibroblast growth factor receptor (FGFR): FGFR plays an important role in the process of fibrosis. The inhibitory effect of nintedanib helps reduce the proliferation of fibroblasts, thereby slowing down the process of fibrosis.

3) Platelet-derived growth factor receptor (PDGFR): Activation of PDGFR is one of the important ways to trigger fibrosis. Nintedanib inhibits this receptor and reduces the activity of fibrosis-related cells, thereby slowing down the progression of fibrosis.

4) Src family kinases: Nintedanib further enhances its anti-fibrotic effect by inhibiting Src family kinases (such as Src, Lyn, Hck, etc.).

2. Anti-fibrosis effect:

By inhibiting the above targets, nintedanib effectively reduces the excessive proliferation of fibroblasts and collagen deposition, and slows down the progression of pulmonary fibrosis. This mechanism of action is of great significance for the treatment of diseases such as idiopathic pulmonary fibrosis (IPF).

3. Effect of therapeutic effect:

The anti-fibrotic effect of nintedanib can help delay the decline of lung function in patients and reduce the rate of loss of lung function. Studies have shown that patients using nintedanib significantly slowed the decline in lung function and improved their quality of life. Nintedanib also effectively reduces the risk of acute exacerbations in patients, thereby reducing the need for hospitalization and treatment.

Keyword tags: nintedanib,Nintedanib, mechanism of action, VEGFR, FGFR, PDGFR, Src family kinase, anti-fibrosis, pulmonary fibrosis

Reference materials:https://www.drugs.com/nintedanib.html